Measurement of Retinal Nerve Fiber Layer Thickness - a Biomarker for the Early Detection of Alzheimer's Disease?

Alzheimer's Disease Clinical Trial

— SCI-OCT  

Official title:

Pilot Study That Investigates the Potential of Using OCT (Optical Coherence Tomography) Measurements of the Thickness of the Retinal Nerve Fiber Layer as a Biomarker for the Early Detection of Alzheimer's Disease.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02051244
• Other study ID #: CMC-13-0094-CTIL
• Status: Not yet recruiting
• Phase: N/A
• First received: January 26, 2014
• Last updated: January 30, 2014
• Start date: February 2014
• Est. completion date: February 2015

Study information

• Verified date: January 2014
• Source: Carmel Medical Center
• Contact: Faith H Goldberg, MBBS
• Phone: 092 4 9832914
• Email: faith.goldberg[@]fosanet.org
• Is FDA regulated: No
• Health authority: Israel: Ethics Commission
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine whether by measuring changes in the thickness of the retinal nerve fibre layer (the photosensitive layer at the back of the eye) you could predict if someone would develop Alzheimer's disease in the future. The measurement is made by OCT (ocular coherence tomography), a noninvasive and relatively inexpensive test that uses light waves to scan the back of the eye.

Description:

Alzheimer's Disease (AD) is a degenerative neurological disorder characterized by the insidious onset of a progressive decline in cognitive function. It is the most common form of dementia affecting an estimated 26 million people worldwide in 2006, a number that is expected to quadruple by 2050 due to the anticipated increase in life expectancy. Difficulty remembering names and recent events is often an early clinical symptom as is apathy and depression. Later symptoms include impaired judgment, disorientation, confusion, behavior changes and difficulty in swallowing and walking.

New criteria and guidelines for diagnosing Alzheimer's published in 2011 recommend that it be considered a disease that begins well before the development of symptoms. Brain changes in individuals with Alzheimer's are thought to begin 10 years or more before symptoms such as memory loss occur - the asymptomatic preclinical phase of AD. Researchers believe that treatment to slow down or stop progression of Alzheimer's and preserve brain function will be most effective when administered early in the course of the disease. The pursuit of biomarkers to detect asymptomatic preclinical AD is a current issue and potential biomarkers such as: brain volume, level of glucose metabolism in the brain, levels of beta-amyloid and tau in the CSF, detection of apoptosing retinal cells (DARC), are being investigated. In this study we would like to propose the measurement of retinal nerve fiber layer thickness as a potential key biomarker for the detection of asymptomatic preclinical Alzheimer's and Mild Cognitive Impairment (MCI).

The eye can be considered a window to the brain and the retina exists as an extension of the CNS. Changes that occur in the retina can be visualized non-invasively and directly with increasingly sophisticated imaging techniques. It is now possible to detect changes in single neurons in the eye. Historically the visual symptoms that have been reported in AD patients have been attributed to neuronal damage to the visual pathways in the brain rather than the retina. However there is increasing evidence that shows that the specific pathological findings in the brain occur in the retina also.

The ocular manifestations in AD were first documented by Cogan in 1985, who documented deficits in visual acuity, contrast sensitivity, colour vision and motion perception. In more recent studies using optical coherence tomography (OCT), peripapillary thinning of the retinal nerve fiber layer (RNFL) has been demonstrated, occurring initially superiorly and causing inferior visual field loss.

The use of OCT as a non-invasive optical imaging technique has become an accepted method for assessing the thickness of the RNFL due to its reproducibility and accuracy. Blanks et al. provided ultrastructural studies that showed retinal ganglion cell degeneration in post mortem retinas of patients with AD. He demonstrated that in AD extensive neuronal loss was seen throughout the retina but most pronounced in superior and inferior quadrant and loss in the central retina, the greatest decrease of neurons being in the temporal foveal region.

Results of a study by C. Paquet, M.Boissonnot et al demonstrated an abnormal RNFL thickness in patients with amnestic Mild Cognitive Impairment (MMSE score of 25, with subjective memory complaints), suggesting that the involvement of the retina is an early event in the development of Alzheimer's.

MCI is generally defined as being problems with memory, language or another essential cognitive ability that are severe enough to show up on cognitive tests but not to interfere with daily life. Studies show that 10 -20 % of people aged 65 and older have MCI. 15% of individuals with MCI progress to dementia each year. No significant difference was found between RNFL thickness observed in MCI patients and in mild AD patients.

In light of these findings it is proposed that measurement of RNFL could be used to enable early MCI diagnosis in patients suffering from subtle memory disturbances and as a biomarker to detect asymptomatic pre-clinical Alzheimer's disease. In light of these findings this study proposes to take investigations one step further and to see if patients suffering from subjective memory loss but with normal cognitive tests have abnormal RNFL tests.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: February 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• age 60 and above

• able to read, understand and sign independently a consent form

• able to undergo a cognitive test

• results of their cognitive test fall into one of the three cohort groups

Exclusion Criteria:

• other diseases affecting the optic nerve such as glaucoma

• unclear media such as dense cataracts that will not allow assessment by OCT

• Cognitive test scores that are less than mild cognitive impairment

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease

Locations

Country	Name	City	State
Israel	Carmel Medical Center	Haifa

Sponsors (1)

Lead Sponsor	Collaborator
Carmel Medical Center

Country where clinical trial is conducted

Israel, 

References & Publications (3)

Kesler A, Vakhapova V, Korczyn AD, Naftaliev E, Neudorfer M. Retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Clin Neurol Neurosurg. 2011 Sep;113(7):523-6. doi: 10.1016/j.clineuro.2011.02.014. Epub 2011 Mar 31. — View Citation

Lu Y, Li Z, Zhang X, Ming B, Jia J, Wang R, Ma D. Retinal nerve fiber layer structure abnormalities in early Alzheimer's disease: evidence in optical coherence tomography. Neurosci Lett. 2010 Aug 9;480(1):69-72. doi: 10.1016/j.neulet.2010.06.006. Epub 2010 Jun 8. — View Citation

Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, Hugon J. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett. 2007 Jun 13;420(2):97-9. Epub 2007 Mar 19. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement of retinal nerve fiber layer thickness	The subject will undergo a full eye examination including visual acuity, intraocular pressure and fundoscopy. This will be followed by an OCT test.	a once off measurement which will be performed within a year of recruitment to the study	No
Secondary	Cognitive function	The subject will undergo the following cognitive tests - MMSE (Mini Mental State Examination) and SLUMS (St.Louis University Mental Status Examination).	a once off assessment that will be performed within a month of the opthalmic examination and OCT test. This will be completed within a year of recruitment to the study	No

External Links

•   2011 Alzheimer's Disease Facts and Figures
•   Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease
•   Retinal nerve fiber layer structure abnormalities in early Alzheimer's disease: Evidence in optical coherence tomography
•   Retinal thickness in patients with mild cognitive impairment and Alzheimer's disease